This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Not all investors can use a backdoor Roth. This intro clarifies eligibility and the basic implementation steps.
27,669 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Florida launches a staged crackdown on crypto ATMs, requiring warnings, receipts, caps, and a 72-hour refund for firs...
The housing story of 2026 isn’t about a vanished dream. It’s about where the American Dream still thrives—where build...
The Craig Tann Group in Las Vegas posted nearly $486 million in 2025 sales, earning No. 10 in national sales volume a...
As a NATO summit approaches this week in Turkey, Trump shifts the debate from defense spending to loyalty, challengin...
Tesla shares rise on stronger robotaxi momentum and robust delivery data, sparking a broader EV rally as Rivian, Luci...
ADA pulled back after a sharp weekly surge, with derivatives data signaling waning momentum and potential shifts in t...
An unknown wallet moved $21.2 million of BONK tokens through a governance vote, draining the BonkDAO treasury and tri...
Ethereum fails to sustain a rebound toward the $2,000 level as a fresh pullback tests support and resistance dynamics...
PepsiCo trims snack prices in North America to spur demand, but the pause in regional growth keeps investors focused ...
A New York judge denied Kalshi’s bid for an injunction, keeping state gambling laws in play as federal rulemaking on ...
Coinbase reports a resilient services business while MicroStrategy shoulders heavy bitcoin exposure and fixed costs a...